Bilateral Linear Porokeratosis Treated With Topical Cholesterol 2%/Lovastatin 2.
bilateral linear porokeratosis
blashko
cholesterol
lovastatin
mevalonate
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
31
07
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
6
9
2022
Statut:
epublish
Résumé
Linear porokeratosis is a cutaneous disorder that typically presents in a unilateral linear formation. While the exact cause of linear porokeratosis is unknown, it is thought to be a downstream effect of disrupted cholesterol synthesis and mevalonate accumulation. Our patient is a 61-year-old male with an unusual case presentation of bilateral linear porokeratosis. He had failed numerous standard therapies. Pathologic examination of a skin biopsy was consistent with bilateral linear porokeratosis. Through a PubMed search, there have been limited reported cases of unilateral linear porokeratosis, but there have not been any reported cases of bilateral linear porokeratosis. There are currently limited therapies with satisfactory outcomes for variants of porokeratosis. While there are some studies on the topical application of cholesterol/lovastatin, limited studies have been performed on the linear form. Our study evaluates the efficacy of compounded topical cholesterol 2%/lovastatin 2% ointment on bilateral linear porokeratosis. The patient demonstrated a significant reduction of porokeratotic lesions on the treated arm compared to the untreated arm. Cholesterol/lovastatin is alternative therapy that can be considered in the treatment of linear porokeratosis and other porokeratosis variants.
Identifiants
pubmed: 36060323
doi: 10.7759/cureus.27540
pmc: PMC9428266
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e27540Informations de copyright
Copyright © 2022, Diep et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA Dermatol. 2019 May 1;155(5):548-555
pubmed: 30942823
Cell. 2018 Jan 11;172(1-2):135-146.e9
pubmed: 29328908
J Am Acad Dermatol. 2020 Jan;82(1):123-131
pubmed: 31449901
Br J Dermatol. 2016 Dec;175(6):1342-1345
pubmed: 27086492
Am J Dermatopathol. 2015 Feb;37(2):145-55
pubmed: 24423932
Pediatr Dermatol. 2021 Jan;38(1):242-245
pubmed: 33170511
An Bras Dermatol. 2018 Jun;93(3):477-478
pubmed: 29924219